Sanofi: acquires an antibody from Dren Bio

(CercleFinance.com) - Sanofi announces an agreement with Dren Bio to acquire DR-0201, a targeted bispecific antibody that engages myeloid cells for robust B-cell depletion, as demonstrated in early pre-clinical and clinical studies.


Dren Bio's deep B-cell depletion agent has the potential to reprogram the immune system, the healthcare group says, which sees this acquisition as an additional asset to reinforce its leadership in the immunology sphere.

Sanofi will acquire DR-0201 for an upfront payment of $600m, followed by potential future payments totaling $1.3bn, subject to the achievement of development and commercialization milestones.

Subject to closing conditions, including regulatory approval, this transaction, which will be financed by available cash, is expected to close in Q2 2025.


Copyright (c) 2025 CercleFinance.com. All rights reserved.